These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 30107372)

  • 1. Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
    Imai H; Yamada Y; Sugiyama T; Minemura H; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Chemotherapy; 2018; 63(3):181-189. PubMed ID: 30107372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Post-progression survival is highly linked to overall survival in patients with non-small-cell lung cancer harboring sensitive EGFR mutations treated with first-line epidermal growth factor receptor-tyrosine kinase inhibitors.
    Imai H; Kaira K; Mori K; Kotake M; Mitani M; Kawashima N; Hisada T; Minato K
    Thorac Cancer; 2019 Dec; 10(12):2200-2208. PubMed ID: 31595714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
    Imai H; Minemura H; Sugiyama T; Yamada Y; Kaira K; Kanazawa K; Kasai T; Kaburagi T; Minato K;
    Cancer Chemother Pharmacol; 2018 Jul; 82(1):119-127. PubMed ID: 29737372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
    Yoshida T; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Ohe Y; Goto K
    Lung Cancer; 2015 Dec; 90(3):477-83. PubMed ID: 26604031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.
    Xu J; Zhang X; Yang H; Ding G; Jin B; Lou Y; Zhang Y; Wang H; Han B
    Oncotarget; 2016 Oct; 7(42):68442-68448. PubMed ID: 27637087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of EGFR-TKI Rechallenge Treatment in Elderly Patients with Advanced Non-Small-Cell Lung Cancer Harboring Drug-Sensitive EGFR Mutations.
    Yamada Y; Imai H; Sugiyama T; Minemura H; Kanazawa K; Kasai T; Minato K; Kaira K; Kaburagi T
    Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577852
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of clinical parameters on progression-free survival of non-small cell lung cancer patients harboring EGFR-mutations receiving first-line EGFR-tyrosine kinase inhibitors.
    Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Lin MC
    Lung Cancer; 2016 Mar; 93():47-54. PubMed ID: 26898614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK; Hahn S; Kim DW; Suh KJ; Keam B; Kim TM; Lee SH; Heo DS
    JAMA; 2014 Apr; 311(14):1430-7. PubMed ID: 24715074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.
    Chang GC; Tseng CH; Hsu KH; Yu CJ; Yang CT; Chen KC; Yang TY; Tseng JS; Liu CY; Liao WY; Hsia TC; Tu CY; Lin MC; Tsai YH; Hsieh MJ; Wu WS; Chen YM
    Lung Cancer; 2017 Feb; 104():58-64. PubMed ID: 28213001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
    Zhou Q; Yang JJ; Chen ZH; Zhang XC; Yan HH; Xu CR; Su J; Chen HJ; Tu HY; Zhong WZ; Yang XN; Wu YL
    J Hematol Oncol; 2016 Sep; 9(1):86. PubMed ID: 27619632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational study.
    Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Bria E; Spitaleri G; Rossi A; Novello S
    Lung Cancer; 2016 May; 95():73-81. PubMed ID: 27040855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy.
    Kotake M; Miura Y; Imai H; Mori K; Sakurai R; Kaira K; Tomizawa Y; Minato K; Saito R; Hisada T
    Chemotherapy; 2017; 62(4):205-213. PubMed ID: 28380484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
    Chen Q; Quan Q; Ding L; Hong X; Zhou N; Liang Y; Wu H
    Oncotarget; 2015 Sep; 6(28):24904-11. PubMed ID: 26172562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.